Article
Mutation and cell state compatibility is required and targetable in Ph <i>+</i> acute lymphoblastic leukemia minimal residual disease
2024-06-10
Abstract excerpt
<h4>SUMMARY</h4> Efforts to cure BCR::ABL1 B cell acute lymphoblastic leukemia (Ph+ ALL) solely through inhibition of ABL1 kinase activity have thus far been insufficient despite the availability of tyrosine kinase inhibitors (TKIs) with broad activity against resistance mutants. The mechanisms that drive persistence within minimal residual disease (MRD) remain poorly understood and therefore untargeted. Utilizin...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8966437b-fd71-5dc8-8b5e-e44d0cf2a0c6
- DOI
- 10.1101/2024.06.06.597767
